一个基于试验的经济评估的CaFaSpA转诊策略为轴性脊柱关节炎
M Jamal1, T M Kuijper1, Jmw Hazes2
1Department of Rheumatology and Clinical Immunology, Maasstad Hospital, Rotterdam, The Netherlands.
Scandinavian journal of rheumatology
|August 31, 2023
概括
在慢性腰部疼痛 (CLBP) 患者中,轴性脊柱关节炎 (axSpA) 的数字CaFaSpA转诊策略 (CS) 并没有恶化健康结果,但降低了成本. 这种数字推模式是初级保健的成本效益高的选择.
科学领域:
- 卫生经济学 卫生经济学
- 类风湿病学 类风湿病学
- 主要护理是指初级护理.
背景情况:
- 慢性腰部疼痛 (CLBP) 是一种常见的疾病,通常与轴性脊柱关节炎 (axSpA) 重叠.
- 及时和准确的转诊对于有效的axSpA管理至关重要.
- 数字推策略有可能提高初级保健的效率.
研究的目的:
- 与常规护理 (UC) 相比,评估数字CaFaSpA转诊策略 (CS) 的成本效益.
- 从医疗保健和社会角度评估CS对患者结果和医疗保健成本的影响.
主要方法:
- 在荷兰进行了一个集群随机对照试验.
- 90个通用实践集群被随机分配到CS或UC.
- 经济评估包括12个月的直接医疗和间接成本,使用RMDQ和EQ-5D-3L.等措施.
主要成果:
- 在12个月后,CS和UC组之间没有观察到残疾 (RMDQ) 或生活质量 (EQ-5D-3L) 的显著差异.
- 该CS集团的总成本显著降低,主要是由于减少了生产力损失.
- 增量成本效益比率 (ICUR) 用于RMDQ和质量调整寿命年 (QALY) 进行计算.
结论:
- 数字 CaFaSpA 转诊策略是对 axSpA. axSpA 风险的 CLBP 初级保健患者常规护理的经济有效的替代方案.
- 这种数字化方法不会损害患者的健康状况,并且可以促进及时获得适当的护理.
- CS代表了一种有价值的初级保健转诊模型,可以加速 axSpA.的诊断和治疗.
更多相关视频
08:33Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
Published on: January 5, 2024
1.2K
06:28Biomechanical Changes Related to Low Back Pain: An Innovative Tool for Movement Pattern Assessment and Treatment Evaluation in Rehabilitation
Published on: December 13, 2024
559
相关概念视频
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...